I-MAB SPONS.ADS/1 -0001 (F:0VY) — Market Cap & Net Worth
Market Cap & Net Worth: I-MAB SPONS.ADS/1 -0001 (0VY)
I-MAB SPONS.ADS/1 -0001 (F:0VY) has a market capitalization of $268.17 Million (€229.38 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #15424 globally and #1485 in its home market, demonstrating a -7.87% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying I-MAB SPONS.ADS/1 -0001's stock price €1.99 by its total outstanding shares 115266053 (115.27 Million).
I-MAB SPONS.ADS/1 -0001 Market Cap History: 2020 to 2026
I-MAB SPONS.ADS/1 -0001's market capitalization history from 2020 to 2026. Data shows change from $4.45 Billion to $268.17 Million (-25.16% CAGR).
I-MAB SPONS.ADS/1 -0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how I-MAB SPONS.ADS/1 -0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 0VY by Market Capitalization
Companies near I-MAB SPONS.ADS/1 -0001 in the global market cap rankings as of May 5, 2026.
Key companies related to I-MAB SPONS.ADS/1 -0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
I-MAB SPONS.ADS/1 -0001 Historical Marketcap From 2020 to 2026
Between 2020 and today, I-MAB SPONS.ADS/1 -0001's market cap moved from $4.45 Billion to $ 268.17 Million, with a yearly change of -25.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €268.17 Million | -40.42% |
| 2025 | €450.09 Million | +300.00% |
| 2024 | €112.52 Million | -49.39% |
| 2023 | €222.35 Million | -50.60% |
| 2022 | €450.09 Million | -91.69% |
| 2021 | €5.42 Billion | +21.82% |
| 2020 | €4.45 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of I-MAB SPONS.ADS/1 -0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $268.17 Million USD |
| MoneyControl | $268.17 Million USD |
| MarketWatch | $268.17 Million USD |
| marketcap.company | $268.17 Million USD |
| Reuters | $268.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About I-MAB SPONS.ADS/1 -0001
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial fo… Read more